Compounding Document Vaccines 
Pharmaceutical Technology
SEPTEMBER 15, 2022
Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.
Omnicell
JANUARY 10, 2023
Howard Montgomery, MS, RPh Director, Clinical Consulting, Omnicell The biggest vaccination campaign in history is now underway and scaling fast. The vaccine rollout brings unique logistical challenges, especially for health system pharmacy as they need to manage inventory across multiple, diverse locations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JUNE 27, 2022
A guidance document has been released to support these activities. A potential first-in-class compound to treat dengue fever is currently undergoing Phase I clinical development, as is a potential drug candidate for Cryptosporidium infection, EDI048. LXE408 is currently entering Phase II clinical development.
STAT
NOVEMBER 18, 2022
The document says that public funding for the development of vaccines and treatments should be more transparent, and include provisions to ensure that any resulting products are distributed evenly around the world. The agency issued 62 warning letters and 23 import alerts related to drugs, excluding compound-related actions.
European Pharmaceutical Review
JANUARY 16, 2023
He warned, “Implementation of a CCS will require more than writing documents.”. MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. The previous record for vaccine development and approval was four years for the measles vaccine.
pharmaphorum
JANUARY 9, 2023
1 Kenya, for example, entered the pandemic with no human vaccines manufacturing facility and established the BioVax institute for local vaccine manufacture with a major plant investment starting in 2023. For pharma, the impact in critical areas such as the performance of newly marketed innovation has already been documented.
ISPE
OCTOBER 26, 2022
ATMP facilities are different from conventional pharmaceutical facilities that process other traditional modalities, such as vaccines and monoclonal antibodies (mAbs), and often require heightened segregation and smaller footprints. Complete Data Gathering. Outline Guiding and Segregation Principles.
Expert insights. Personalized for you.
108 
Let's personalize your content